Truist raises American Healthcare REIT stock price target on growth By Investing.com

Truist raised its price target on American Healthcare REIT (AHR) to $57 from $52 while maintaining a Buy; the stock has risen ~85% over the past 12 months (InvestingPro cites 89.6%) and trades near its 52-week high of $54.67. AHR reported Q4 2025 EPS of $0.06 and revenue of $604.08M, with normalized FFOps of $0.46 and consensus-aligned guidance; analysts project ~18% revenue growth for 2026 and a 9.4% average annual FFOps growth over five years. The company launched a $1.75B at-the-market equity program (using major underwriters) and holds a ~$10B market cap, signaling strengthened capital access to fuel growth despite higher recurring capex in its independent senior housing portfolio.

Analysis

The new equity issuance optionality meaningfully shifts the firm from a cash-conservation posture to an acquisition-and-capex engine; if management draws the program it buys growth without levering the balance sheet but also expands free float, creating a two-stage trade: near-term supply pressure and medium-term accretion if deployed into higher-yielding assets. Independent senior-housing assets that require steady capital reinvestment are the weakest link — recurring capex drives timing risk on distributable cash and can turn an otherwise stable FFO cadence into lumpy quarterly beats/misses. Market technicals matter here: trading at multi-month highs compresses the margin for execution missteps — a single quarter of lower-than-expected funds-available-for-distribution or an uptick in interest rates could force an outsized re-rate. Longer-term, demographic tailwinds are intact but will only justify a premium multiple if management converts float into demonstrably higher, stable cash yields; the key catalysts to watch are cadence of ATM utilization, guidance on capital deployment, and occupancy trends in the capital-intensive independent housing subportfolio.

Key Decisions for Investors

• Long AHR shares on a controlled pullback: accumulate on a 5-8% intraday retreat from current levels, target 18-30% total return over 9–12 months (driven by accretive deployment + multiple re-rating), set a tactical stop-loss at 8% to limit dilution/ATM execution risk.
• Call-spread alternative for defined risk: buy a 6–12 month AHR call spread (e.g., buy near-term ITM/ATM call and sell a call ~20–30% higher) to capture upside from accretive capital deployment with max loss limited to premium paid; target 2.5x–4x payoff if ATM is used accretively.
• Protective hedge: purchase 3-month puts sized to 20–30% of equity exposure to guard against short-term dilution or an occupancy miss; this keeps upside participation while capping drawdown from near-term technical selloffs.
• Pair trade to isolate execution alpha: go long AHR and short a broad REIT ETF (e.g., VNQ) or a more cyclical senior-housing operator for 3–6 months to capture potential idiosyncratic outperformance if management deploys capital accretively; size the short to neutralize interest-rate and macro REIT beta, target asymmetric return if AHR executes (>15% gross upside vs limited downside if hedged).